Please assess the completion status of the following clinical trial:

Trial Title: Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion criteria~* Male and female adult patients ≥ 18 years old and ≤ 75 years.~* Patients with a documented physician diagnosis of asthma for a period of at least 12 months prior to Visit 1 (Screening).~* Patients who have used ICS and LABA combinations for asthma for at least 3 month and at a stable medium or high dose of ICS for at least 1 month prior to Visit 1 (Screening).~* Pre-bronchodilator FEV1 of \< 80 % of the predicted normal value at screening Visit 1 (spirometry will not be repeated at baseline prior to randomization).~* Patients who demonstrate an increase in FEV1 of ≥ 12 % and 200 mL after administration of 400 µg salbutamol/360 µg albuterol (or equivalent do se) at Visit 1 (Screening). All patients must perform a reversibility test at Visit 1 (Screening). If reversibility is not demonstrated at Visit 1 (Screening), then, reversibility testing may be repeated once during the screening period.~* If reversibility is not demonstrated at Visit 1 (retesting allowed once), patients must be screen failed. Spacer devices are not permitted during reversibility testing Key Exclusion criteria~* Patients who have smoked or inhaled tobacco products within the 6 month period prior to Visit 1~* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1~* Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention~* Patients who have had a respiratory tract infection or asthma worsening within 4 weeks prior to Visit 1~* Patients with any chronic conditions affecting the upper respiratory tract~* Patients with a history of chronic lung diseases other than asthma, including (but not limited to) COPD, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.~* Patients with Type I diabetes or uncontrolled Type II diabetes (HbA1c \>9% at screening).~* Patients who have a clinically significant ECG abnormality at Visit 1~* Patients with a history of hypersensitivity or intolerance to any of the study drugs (including excipients)~* Patients with narcolepsy and/or insomnia.~* Patients on Maintenance Immunotherapy (desensitization) for allergies for less than 3 months prior to Visit 2 or patients on Maintenance Immunotherapy for more than 3 months prior to Visit 2 but expected to change throughout the course of the study.~* Pregnant or nursing (lactating) women~* Women of child-bearing potential must use Highly effective contraception methods~* Patients who have discontinued LAMA therapy in the past for any safety, tolerability or perceived lack of efficacy reason.~* History of paradoxical bronchospasm in response to inhaled medicines.~* Patients with a history of clinically relevant bronchoconstriction upon repeated forced expiratory maneuvers.~* Patient with a serum potassium level below the laboratory limit of normal at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: ACTIVE_COMPARATOR): A-B-C
- Sequence 2 (Type: ACTIVE_COMPARATOR): A-C-B
- Sequence 3 (Type: ACTIVE_COMPARATOR): B-C-A
- Sequence 4 (Type: ACTIVE_COMPARATOR): B-A-C
- Sequence 5 (Type: ACTIVE_COMPARATOR): C-A-B
- Sequence 6 (Type: ACTIVE_COMPARATOR): C-B-A

Based on this trial design, predict the completion outcome and termination type (if applicable).